Lupus News and Research

Latest Lupus News and Research

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose parkinsonian syndromes.

15 Nov 2012

Exposure to uranium may increase lupus rates

People living near a former uranium ore processing facility in Ohio are experiencing a higher than average rate of lupus, according a new study conducted by scientists at the University of Cincinnati and Cincinnati Children's Hospital Medical Center.

14 Nov 2012

Lupus may carry pregnancy complication risk

US researchers report that women with systemic lupus erythematosus have a twofold higher risk for developing preeclampsia than women without an autoimmune disease.

6 Nov 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Musculoskeletal ultrasound being increasingly used for diagnosis and management of rheumatic diseases

More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.

29 Oct 2012

Researchers discover that bean commonly used in Chinese cuisine protects against sepsis

Researchers at The Feinstein Institute for Medical Research have discovered that a bean commonly used in Chinese cuisine protects against the life-threatening condition sepsis.

29 Oct 2012

HSS announces opening of new Lerner Children's Pavilion

The new Pavilion within the #1 hospital for orthopedics in the country affirms HSS' longstanding commitment to championing children and caring for their musculoskeletal conditions.

26 Oct 2012

Feinstein Institute to study overall impact of WTC disaster on responders

The Feinstein Institute for Medical Research has been awarded a $1 million grant from the World Trade Center Health Program, which is administered by the National Institute for Occupational Safety and Health, part of the US Centers for Disease Control and Prevention, the National Institute for Occupational Safety and Health and Safety to comprehensively study the overall physical, mental and socioeconomic impact of the World Trade Center (WTC) disaster on responders, as well as identify the linkage between socioeconomic status and health among all occupations of WTC responders.

26 Oct 2012

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA (adalimumab) ULTRA 1 and ULTRA 2 studies.

23 Oct 2012

Lupus investigators receive LRI's first $1 million research grants

The Lupus Research Institute (LRI) today announced the first $1 million research grants given to lupus investigators by a private research organization.

19 Oct 2012

UMass professor receives $1 million LRI grant for lupus research

The Lupus Research Institute (LRI) has named University of Massachusetts Medical School Professor of Medicine Ann Marshak-Rothstein, MD, one of two recipients of the first LRI Distinguished Innovator Awards.

17 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Active Biotech and Ipsen have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society for Medical Oncology) held in Vienna September 28-October 2.

1 Oct 2012

Researchers identify IL-27 molecule involved in counterbalancing the immune system attack

We couldn't live without our immune systems, always tuned to detect and eradicate invading pathogens and particles. But sometimes the immune response goes overboard, triggering autoimmune diseases like lupus, asthma or inflammatory bowel disease.

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

Yale University professor receives 2012 Vanderbilt Prize in Biomedical Science

The 2012 Vanderbilt Prize in Biomedical Science has been awarded to Yale University professor Joan Steitz, Ph.D., whose pioneering work has helped reveal and clarify the complexities of RNA and the roles that RNA molecules play in health and disease.

11 Sep 2012

RNA researcher to receive 2012 Pearl Meister Greengard Prize from The Rockefeller University

Joan A. Steitz, Ph.D., a pioneer in the field of RNA biology whose discoveries involved patients with a variety of autoimmune diseases, will be awarded the 2012 Pearl Meister Greengard Prize from The Rockefeller University. The prize, which honors female scientists who have made extraordinary contributions to biomedical science and carries an honorarium of $100,000, will be presented at a ceremony on Thursday, November 29 at Rockefeller University's Caspary Auditorium.

11 Sep 2012

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.

6 Sep 2012